Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells

International Journal of Cancer

Volumn 136, Issue 5, 2015, Pages 1085-1094

  Deauvieau, Florence ^a,b,c   Ollion, Vincent ^a,b,c,d   Doffin, Anne Claire ^a,b,c   Achard, Carole ^e   Fonteneau, Jean François ^e   Verronese, Estelle ^a,b,c   Durand, Isabelle ^a,b,c   Ghittoni, Raffaella ^c   Marvel, Jacqueline ^c   Dezutter Dambuyant, Colette ^a,b,c   Walzer, Thierry ^c   Vie, Henri ^e   Perrot, Ivan ^f   Goutagny, Nadège ^a,b,c,d   Caux, Christophe ^a,b,c,d   Valladeau Guilemond, Jenny ^a,b,c,d  

^a CENTRE LÉON BÉRARD   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d LabEx DEVweCAN   (France)

^e UNIVERSITÉ DE NANTES   (France)

^f INNATE PHARMA   (France)

Author keywords

Cross presentation; Dendritic cell; mAb therapy; NK cell

Indexed keywords

CD11B ANTIGEN; CD141 ANTIGEN; CD34 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; HLA A2 ANTIGEN; LYMPHOCYTE ANTIGEN; NY ESO 1 ANTIGEN; OVALBUMIN; RITUXIMAB; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; K562 CELL LINE; MCF 7 CELL LINE; MONOCYTE DERIVED DENDRITIC CELL; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; T LYMPHOCYTE ACTIVATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTATION; IMMUNOLOGY; NEOPLASM; PATHOLOGY; TUMOR CELL CULTURE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CROSS-PRIMING; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84918821777     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29087     Document Type: Article

References (49)

1. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64.
2. Uhl M, Kepp O, Jusforgues-Saklani H, et al. Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virusspecific CD81 T cells. Cell Death Differ 2009;16:991-1005.
3. Harshyne LA, Watkins SC, Gambotto A, et al. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001;166:3717-23.
4. Maranon C, Desoutter JF, Hoeffel G, et al. Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD41 T lymphocytes. Proc Natl Acad Sci USA 2004;101:6092-7.
5. Matheoud D, Baey C, Vimeux L, et al. Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model. PLoS One 2011;6:e19104.
6. Shortman K, Heath WR. The CD81 dendritic cell subset. Immunol Rev 2010;234:18-31.
7. Hildner K, Edelson BT, Purtha WE, et al. Batf3 deficiency reveals a critical role for CD8alpha1 dendritic cells in cytotoxic T cell immunity. Science 2008;322:1097-100.
8. Bachem A, Guttler S, Hartung E, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c1CD1411 cells as homologues of mouse CD81 dendritic cells. J Exp Med 2010;207:1273-81.
9. Haniffa M, Shin A, Bigley V, et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD1031 nonlymphoid dendritic cells. Immunity 2012;37:60-73.
10. Crozat K, Guiton R, Contreras V, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha1 dendritic cells. J Exp Med 2010;207:1283-92.
11. Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD1411 (BDCA-3) 1 dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010;207:1247-60.
12. Poulin LF, Salio M, Griessinger E, et al. Characterization of human DNGR-11 BDCA31 leukocytes as putative equivalents of mouse CD8alpha1 dendritic cells. J Exp Med 2010;207:1261-71.
13. Cohn L, Chatterjee B, Esselborn F, et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA31 dendritic cells at cross presentation. J Exp Med 2013;210:1049-63.
14. Segura E, Durand M, Amigorena S. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med 2013;210:1035-47.
15. Gerosa F, Baldani-Guerra B, Nisii C, et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327-33.
16. Srivastava RM, Lee SC, Andrade Filho PA, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013;19:1858-72.
17. Agaugue S, Marcenaro E, Ferranti B, et al. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood 2008;112:1776-83.
18. Piccioli D, Sbrana S, Melandri E, et al. Contactdependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002;195:335-41.
19. Tanaka F, Hashimoto W, Okamura H, et al. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Cancer Res 2000;60:4838-44.
20. Dao T, Gomez-Nunez M, Antczak C, et al. Natural killer cells license dendritic cell crosspresentation of B lymphoma cell-associated antigens. Clin Cancer Res 2005;11:8763-72.
21. Mailliard RB, Son YI, Redlinger R, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 2003;171:2366-73.
22. Retiere C, Prod'homme V, Imbert-Marcille BM, et al. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response. J Virol 2000;74:3948-52.
23. Guillerme JB, Boisgerault N, Roulois D, et al. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res 2013;19:1147-58.
24. Rabinovich BA, Li J, Shannon J, et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J Immunol 2003;170:3572-6.
25. Castiglioni P, Martin-Fontecha A, Milan G, et al. Apoptosis-dependent subversion of the Tlymphocyte epitope hierarchy in lymphoma cells. Cancer Res 2002;62:1116-22.
26. Labarriere N, Bretaudeau L, Gervois N, et al. Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int J Cancer 2002;101:280-6.
27. Menager MM, Menasche G, Romao M, et al. Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. Nat Immunol 2007;8:257-67.
28. Walzer T, Dalod M, Robbins SH, et al. Naturalkiller cells and dendritic cells: "l'union fait la force". Blood 2005;106:2252-8.
29. Matheoud D, Perie L, Hoeffel G, et al. Cross-presentation by dendritic cells from live cells induces protective immune responses in vivo. Blood 2010;115:4412-20.
30. Strehl B, Seifert U, Kruger E, et al. Interferongamma, the functional plasticity of the ubiquitinproteasome system, and MHC class I antigen processing. Immunol Rev 2005;207:19-30.
31. Saccheri F, Pozzi C, Avogadri F, et al. Bacteriainduced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med 2010;2:44ra57.
32. Bausero MA, Gastpar R, Multhoff G, et al. Alternative mechanism by which IFN-gamma enhances tumor recognition: active release of heat shock protein 72. J Immunol 2005;175:2900-12.
33. Wolfers J, Lozier A, Raposo G, et al. Tumorderived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001;7:297-303.
34. Semino C, Ceccarelli J, Lotti LV, et al. The maturation potential of NK cell clones toward autologous dendritic cells correlates with HMGB1 secretion. J Leukoc Biol 2007;81:92-9.
35. Vitale M, Della CM, Carlomagno S, et al. NKdependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005;106:566-71.
36. Segura E, Valladeau-Guilemond J, Donnadieu MH, et al. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med 2012;209:653-60.
37. Chao MP, Weissman IL, Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 2012;24:225-32.
38. Perrot I, Deauvieau F, Massacrier C, et al. TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J Immunol 2010;185:2080-8.
39. Robbins SH, Walzer T, Dembele D, et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol 2008;9:R17.
40. Dorner BG, Dorner MB, Zhou X, et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD81 T cells. Immunity 2009;31:823-33.
41. Krebs P, Barnes MJ, Lampe K, et al. NK-cellmediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood 2009;113:6593-602.
42. Adam C, King S, Allgeier T, et al. DC-NK cell cross talk as a novel CD41 T-cell-independent pathway for antitumor CTL induction. Blood 2005;106:338-44.
43. Mocikat R, Braumuller H, Gumy A, et al. Natural killer cells activated by MHC class I (low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003;19:561-9.
44. Liu C, Lou Y, Lizee G, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008;118:1165-75.
45. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximabdependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-9.
46. Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010;18:160-70.
47. Nasser R, Pelegrin M, Michaud HA, et al. Longlasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol 2010;84:10169-81.
48. Abes R, Gelize E, Fridman WH, et al. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010;116:926-34.
49. Westwood JA, Kelly JM, Tanner JE, et al. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD41 T cell pathway. J Immunol 2004;172:757-61.